Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07469475 · ClinicalTrials.gov registry record · Phase 1
Effect of a Daily Supplement on Plasma PAI-1 Levels
A Phase 1 study of Aging and Endothelial Dysfunction, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT07469475 is a Phase 1 study of Aging and Endothelial Dysfunction that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 35 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07469475, a Phase 1 study of Aging and Endothelial Dysfunction, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
In a healthy person, the production of nitric oxide (NO) by the endothelium, the inner lining of the blood vessel, is responsible for a) the ability of the blood vessel to dilate so it can increase its blood flow and b) act as an anti-clotting product to prevent blood clotting in those vessels. Under physiological stress either due to the development of a disease such as diabetes or simply from aging, the endothelial cells can be impacted and become dysfunctional, thereby impairing their ability to make NO and even promoting the development of blood clots. When such endothelial dysfunction occurs, it may be a precursor for the future development of cardiovascular (CV) disease like hypertension or coronary artery disease later on in life in these patients. Therefore, the ability to enhance the local production or availability of NO within such affected blood vessels in patients identified as prone to endothelial dysfunction could play a positive role in either preventing or delaying the onset of endothelial dysfunction and subsequent CV disease in such patients. RM is an oral supplement consisting of natural ingredients and the amino acid, L-citrulline. In laboratory experiments with cells from the inner lining of blood vessels, the four components of RM have been shown to increase the concentration of NO and decrease the levels of some aging markers. In our recently completed study (manuscript currently in review), 31 young men and women took the supplement for 14 days and had no serious side effects. The supplement caused the expected potentially beneficial dilation of the blood vessels and decrease in the levels of Plasminogen Activator Inhibitor-1 (PAI-1), whose levels correlate with aging and risk of cardiovascular disease. In this study, healthy participants will consume the supplement for a 6-week period to determine if PAI-1 levels continue to be suppressed and also examine whether the supplement has an effect on other blood markers whose levels can change
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Supplement with ginger extract, L-citrulline, Paullinia cupana, and muira puama
Study Locations (2)
California
- UCLA - Los Angeles
- UCLA The Men's Clinic - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07469475
The ClinicalTrials.gov registry entry for NCT07469475 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Aging appearing as the primary indexed condition, and to 1 intervention - of which Supplement with ginger extract, L-citrulline, Paullinia cupana, and muira puama is the first listed.
NCT07469475 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07469475 about?
NCT07469475 is a clinical study titled "Effect of a Daily Supplement on Plasma PAI-1 Levels". In a healthy person, the production of nitric oxide (NO) by the endothelium, the inner lining of the blood vessel, is responsible for a) the ability of the blood vessel to dilate so it can increase its blood flow and b) act as an anti-clotting product to prevent blood clotting in those vessels. Unde...
What is the current status of trial NCT07469475?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2026-02-24. Estimated completion is 2026-12.
What conditions does trial NCT07469475 study?
This clinical trial studies the following conditions: Aging, Endothelial Dysfunction, Senescence.
What interventions are being tested in trial NCT07469475?
The interventions under investigation include: Supplement with ginger extract, L-citrulline, Paullinia cupana, and muira puama (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07469475?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07469475 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MTOR Inhibitors in Older Adults
RECRUITING · Phase 1
-
Rapalog Pharmacology (RAP PAC) Study
RECRUITING · Phase 1
-
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
RECRUITING · Phase 1
-
Fisetin to Improve Vascular Function in Older Adults
ACTIVE NOT RECRUITING · Phase 1
-
Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women
ACTIVE NOT RECRUITING · Phase 1
-
Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.